New HR-NMIBC molecular analyses to be presented at the 2022 AUA Annual Meeting Durham, NC, May 10, 2022 –  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American […]

For two decades, scientists have been able to identify the molecular signature of specific cancers by isolating the RNA, responsible for dictating which proteins are produced and, by extension, how the cells behave in the body. Now, Neil Hayes, MD, MS, MPH, director of the Center for Cancer Research at the University of Tennessee Health […]

New molecular analyses to be presented at the AACR Annual Meeting 2022 DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral presentation of the discovery and initial clinical utility of a novel signature that identifies patients with head and neck squamous cell carcinoma (HNSCC) […]

The Piedmont Study, a Real-World Data Analysis in Patients Treated with Platinum Doublet Chemotherapy and/or Pembrolizumab, Identifies Predictive Biomarkers for Approved First-Line Treatments in NSCLC DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the completion of its Piedmont Study, conducted in collaboration with Atrium Health Levine […]

GeneCentric CEO Michael Milburn discusses recent company accomplishments and the year ahead, as well as and current trends in biotech and pharma with WRAL TechWire. Read More

Proceeds to expand and commercialize growing pipeline of RNA-based molecular diagnostics Durham, N.C., Nov. 8, 2021 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million. Proceeds will be used to commercialize GeneCentric’s gene signatures and accelerate the […]